INBRIJA

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, Ireland, Italy, Lithuania, Poland.

Active ingredients

The drug INBRIJA contains one active pharmaceutical ingredient (API):

1	Levodopa UNII 46627O600J - LEVODOPA
	According to the current understanding, the symptoms of Parkinson’s disease are related to depletion of dopamine in the corpus striatum. Dopamine does not cross the blood-brain barrier. Levodopa, the precursor of dopamine, crosses the blood brain barrier and relieves the symptoms of the disease.
	Read more about Levodopa

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
INBRIJA Inhalation powder, capsule	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N04BA01	Levodopa	N Nervous system → N04 Anti-parkinson drugs → N04B Dopaminergic agents → N04BA Dopa and dopa derivatives
Discover more medicines within N04BA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1802247, 1802258
IT	Agenzia del Farmaco	048253013, 048253025
LT	Valstybinė vaistų kontrolės tarnyba	1088511, 1088512
PL	Rejestru Produktów Leczniczych	100424346
US	FDA, National Drug Code	10144-342